Skip to main content

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter.

U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading.

Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said.

“When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement.

Read:As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm

Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rates Canopy the equivalent of a buy, which she writes is the only such rating among Canadian weed stocks.

“We believe that Klein has strong insights into where to trim excess fat in the organization given his time on Canopy’s board of directors and as chairman, having already proven in prior roles to be a seasoned executive, and that he is well equipped to take this kind of dramatic / decisive action,” Azer wrote.

Azer also said in the note that Canopy has not yet disclosed either the projected cost savings for its restructuring plans or its updated cultivation capacity.

Don’t miss:Aphria yanks forecast due to coronavirus after strong increase in cannabis sales

In the U.S., Canopy said that it had halted operations at a hemp grow site in Springfield, New York because the market was flooded during the 2019 growing season and that it would use the supply to produce cannabidiol, or CBD, products. The company had previously said it would invest between $100 million to $150 million in its New York operations.

For Canada, Canopy’s home country, the company said that it was closing its indoor facility in Yorkton, Saskatchewan. The company had previously shut down production facilities in British Columbia and cut 500 jobs as part of the restructuring.

Turning to Africa, Canopy said it had entered into an agreement to sell its operations in Africa and Lesotho.

See also:Aurora Cannabis will roll up its shares in a reverse stock split — here’s what you need to know

Canopy first said it expected a fiscal fourth-quarter charge of C$700 million to C$800 million in March and reiterated Thursday that it continued to expected a charge in that range. Earlier in March, Canopy also closed its corporate-owned weed stores due to the coronavirus outbreak.

The U.S.-listed shares have lost 40.4% over the past three months, while the Cannabis ETF US:THCX has dropped 43.1% and the S&P 500 index US:SPX has declined 16.6%.

Cannabis Watch: Read all of MarketWatch’s cannabis coverage here

Original Article Source: http://www.marketwatch.com/news/story.asp?guid=%7BAF387CE2-7FF7-11EA-ACD4-37694A66548C%7D&siteid=rss&rss=1

Comments

Post a Comment

Popular posts from this blog

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...
Post a Comment
Read more

Can Medical Marijuana Help Aging Parents With Dementia?

For decades, marijuana, even for medical uses, was demonized or questioned.  When states like Colorado legalized it for recreational use, more studies began to determine provable efficacy for its use as a medicine. The Federal government still classifies marijuana the same way it classifies heroin: harmful and with no medical benefits. Now we can see that this is wrong. When states legalized marijuana, referred to as cannabis here, they had an interest in getting data to see what good it could do. Proving efficacy could increase medical marijuana sales, benefit people who might at least find some medical use, and overall would bring tax dollars into the state coffers. Without funding studies, the Federal government has done very little to demonstrate what good cannabis can do. After all, if the presumption is that it helps nothing, there would be no motivation to determine with scientific data that it does anyone any good. But we have convincing data now about its beneficial use ...
Post a Comment
Read more